|
Showing 1 - 2 of
2 matches in All Departments
The hybridoma technique for producing monoclonal antibodies
developed by Drs. Kohler and Millstein in 1975 revolutionized the
field of tumor immunology. It is now clear that there are antigens
associated with or restricted to human neoplasms that have biologic
significance. Monoclonal antibodies have already been demonstrated
to have great immunodiagnostic value, and it is anticipated that
they will become a component of our therapeutic armamentarium. Most
investigators in the field, however, feel the true potential of
monoclonal antibodies in cancer therapy remains to be determined.
Clearly the most encouraging results have been witnessed in the
treatment of hematologic malignancies. This volume of Cancer
Treatment and Research explores the current state of the art of
immunoconjugate therapy of hematologic malignancies. The first
chapter, authored by Drs. Rosen and Kuzel, reviews the current
status of radioimmunotherapy of lymphoma. Results of clinical
investigations utilizing radiolabeled immunoconjugates in B-cell
lymphomas, T-cell lym- phomas, and Hodgkin's disease are discussed.
In addition, obstacles to effective antibody therapy are
highlighted and toxicities are summarized. Chapter 2, written by
Drs. Sgouros and Scheinberg, critiques the treat- ment of leukemia
with radiolabeled monoclonal antibodies. In this chapter, the
unique features of leukemia that make it particularly suitable for
radio- immunotherapy are discussed, an overview of selected
clinical trials is presented, and a treatment planning approach to
radioimmunotherapy in- corporating biologic and physical parameters
is reviewed.
The hybridoma technique for producing monoclonal antibodies
developed by Drs. Kohler and Millstein in 1975 revolutionized the
field of tumor immunology. It is now clear that there are antigens
associated with or restricted to human neoplasms that have biologic
significance. Monoclonal antibodies have already been demonstrated
to have great immunodiagnostic value, and it is anticipated that
they will become a component of our therapeutic armamentarium. Most
investigators in the field, however, feel the true potential of
monoclonal antibodies in cancer therapy remains to be determined.
Clearly the most encouraging results have been witnessed in the
treatment of hematologic malignancies. This volume of Cancer
Treatment and Research explores the current state of the art of
immunoconjugate therapy of hematologic malignancies. The first
chapter, authored by Drs. Rosen and Kuzel, reviews the current
status of radioimmunotherapy of lymphoma. Results of clinical
investigations utilizing radiolabeled immunoconjugates in B-cell
lymphomas, T-cell lym- phomas, and Hodgkin's disease are discussed.
In addition, obstacles to effective antibody therapy are
highlighted and toxicities are summarized. Chapter 2, written by
Drs. Sgouros and Scheinberg, critiques the treat- ment of leukemia
with radiolabeled monoclonal antibodies. In this chapter, the
unique features of leukemia that make it particularly suitable for
radio- immunotherapy are discussed, an overview of selected
clinical trials is presented, and a treatment planning approach to
radioimmunotherapy in- corporating biologic and physical parameters
is reviewed.
|
|